Day: March 5, 2024

Includes late-breaking poster presentation to highlight phase 2 clinical data for tivumecirnon in head and neck cancer SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) — RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced the acceptance of three late-breaking abstracts for poster presentation, including a poster presentation for tivumecirnon (FLX475), its lead oncology drug candidate, highlighting phase 2 clinical data in head and neck squamous cell carcinoma (HNSCC), at the American Association for Cancer Research (AACR) Annual Meeting which will take place April 5-10, 2024 in San Diego, CA. Late-breaking...

– Investigator-initiated trial in patients with relapsed or refractory B-cell non-Hodgkin lymphoma selected for oral presentation SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced that two clinical abstracts have been accepted for presentation at the American Association for Cancer Research (“AACR”) Annual Meeting, which will be held in San Diego from April 5-10, 2024. Session titles and information for the two abstracts are listed below and are now available on the AACR online program planner. A Phase 1 investigator-initiated trial of evorpacept (ALX148), lenalidomide and rituximab for patients with relapsed or refractory...

SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) — Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, announced that three abstracts of new nonclinical data have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024 taking place in San Diego, CA, April 5-10. One oral and two poster presentations will highlight data from Lyell’s product pipeline and research programs, including:An oral presentation on Lyell’s rejuvenation technology which has shown the potential to turn back the epigenetic clock to generate more stem-like T cells with reduced epigenetic age and enhanced proliferation ability A poster presentation of nonclinical data on LYL119, Lyell’s...

MIDLAND, Texas, March 05, 2024 (GLOBE NEWSWIRE) — Viper Energy, Inc. (NASDAQ: VNOM) (“Viper”) announced today the launch of an underwritten public offering of 11,500,000 shares of its Class A common stock by Viper’s parent, Diamondback Energy, Inc. (the “Selling Stockholder”), subject to market and other conditions (the “Secondary Offering”). Viper will not receive any proceeds from the sale of the shares by the Selling Stockholder. The Selling Stockholder has also granted the underwriters a 30-day option to purchase up to an additional 1,725,000 shares of Viper’s Class A common stock. J.P. Morgan, Barclays, Evercore ISI and Goldman Sachs & Co. LLC are acting as joint book-running managers for the Secondary Offering. Copies of the written base prospectus and prospectus supplement for the Secondary Offering, when available,...

SAN FRANCISCO and WALTHAM, Mass., March 05, 2024 (GLOBE NEWSWIRE) — Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis, chronic obstructive pulmonary disease, asthma and other inflammatory and immunology indications (Apogee or the Company), today announced that it has commenced an underwritten public offering of approximately $350.0 million of shares of its common stock. In addition, Apogee expects to grant the underwriters a 30-day option to purchase up to an additional $52.5 million of shares of common stock at the public offering price, less underwriting discounts and commissions. The proposed public offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering...

GUADALAJARA, Mexico, March 05, 2024 (GLOBE NEWSWIRE) — Grupo Aeroportuario del Pacífico, S.A.B. de C.V., (NYSE: PAC; BMV: GAP) (“the Company” or “GAP”) announces preliminary terminal passenger traffic figures for February 2024, compared with February 2023. For February 2024, the total number of terminal passengers at GAP’s 12 Mexican airports increased by 1.1%, compared to February 2023. Puerto Vallarta, Guanajuato, Los Cabos, and Guadalajara presented an increase in passenger traffic of 7.7%, 5.3%, 1.7%, and 0.6%, respectively, compared to February 2023. On the other hand, Montego Bay presented an increase in passenger traffic of 7.8% compared to February 2023. Domestic Terminal Passengers (in thousands):Airport Feb-23 Feb-24 % Change Jan- Feb 23 Jan- Feb 24 % ChangeGuadalajara 913.7 837.2 (8.4 %) 1,904.8 1,748.9 (8.2 %)Tijuana* 636.1 618.9 (2.7 %) 1,349.7 1,297.7 (3.9 %)Puerto...

New luxury homes and villas feature sophisticated options and resort-style amenities in the Seven Shores master-planned communitySeven Shores by Toll BrothersToll Brothers announced its newest luxury villa and single-family home community, Seven Shores in Naples, Florida, is now open for sale.Seven Shores by Toll Brothers“With multiple floor plans designed for today’s buyers and unrivaled personalization options offered at the Toll Brothers Design Studio, residents of Seven Shores will enjoy the best in luxury low-maintenance living with versatile designs and resort-style amenities in desirable Naples,”said Alex Martin, Division President of Toll Brothers in Southwest Florida.Seven Shores by Toll BrothersToll Brothers new luxury homes and villas feature sophisticated options and resort-style amenities in the Seven...

MCLEAN, Va., March 05, 2024 (GLOBE NEWSWIRE) — Freddie Mac (OTCQB: FMCC) announced today the pricing of its first Seasoned Credit Risk Transfer Trust (SCRT) offering of 2024—a securitization of approximately $618 million including both guaranteed senior and non-guaranteed subordinate securities backed by a pool of seasoned re-performing loans (RPLs). The SCRT program is a fundamental part of Freddie Mac’s seasoned loan offerings which reduce less liquid assets in its mortgage-related investments portfolio and shed credit and market risk via economically reasonable transactions. Freddie Mac Seasoned Credit Risk Transfer Trust, Series 2024-1 includes approximately $585 million in guaranteed senior certificates and $32 million in non-guaranteed mezzanine and subordinate certificates. The transaction is expected to settle on...

SAN CARLOS, Calif., March 05, 2024 (GLOBE NEWSWIRE) — Presto Automation Inc. (NASDAQ: PRST), announces that it is canceling its earnings call previously scheduled for 5 pm ET today. The company’s Form 10-Q for the quarter ended December 31, 2024 was filed on February 21, 2024 and the company will communicate business updates and other developments to the market when appropriate. About Presto Automation Inc. Presto (NASDAQ: PRST) provides enterprise-grade AI and automation solutions to the restaurant industry. Our solutions are designed to decrease labor costs, improve staff productivity, increase revenue, and enhance the guest experience. We offer our AI solution, Presto Voice™, to quick service restaurants (QSR) and our pay-at-table tablet solution, Presto Touch, to casual dining chains. Some of the most recognized restaurant...